All In Biotech

Drug Trial Radar · NCT05998941

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study

Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 2023

Primary completion

Feb 2025

Study completion Jun 2025

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

Conditions

  • Cervical Cancer

Interventions

  • TQB2868 injectionDrug

    TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.

  • Paclitaxel injectionDrug

    Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.

  • Cisplatin injectionDrug

    Cisplatin injection can inhibit the DNA replication process of cancer cells

  • Carboplatin injectionDrug

    Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.

  • Bevacizumab injectionDrug

    Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed objective response rate (ORR)Time frame: Baseline to CR or PR ,about 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.